GlassScriptPhysician profile
Madeline Agosto
NPI 1053363580
$2,983.04
in general payments reported to CMS, 2019-2025
37 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $215 · 2021: $312 · 2022: $436 · 2023: $650 · 2024: $500 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.39 | 2021-2024 | Linzess, Viberzi, Vraylar |
| Novo Nordisk INC | $410.23 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.26 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.70 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $130.03 | 2019-2025 | Enflonsia, Vaxelis, Gardasil 9 |
| Axsome Therapeutics, INC. | $126.84 | 2023 | Auvelity |
| Lilly USA, LLC | $122.64 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $107.33 | 2019-2025 | Prolia, Evenity, Otezla |
| Teva Pharmaceuticals USA, INC. | $106.01 | 2024 | Uzedy |
| Astrazeneca Pharmaceuticals LP | $101.85 | 2019-2025 | Farxiga |
| Alkermes, INC. | $90.25 | 2025 | Lybalvi |
| Actelion Pharmaceuticals US, INC. | $75.42 | 2024-2025 | Uptravi, Opsumit |
| Radius Health, INC. | $69.69 | 2024-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $62.02 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $46.13 | 2020-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Agosto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.